Gilead Dives Into Protein Degradation With Nurix Pact

Gilead is elbowing its way into the protein degradation field, seeking to build out a pipeline of oncology drugs in a $45m deal with Nurix. The pool is becoming crowded though, as many other big firms have latched onto this burgeoning field of R&D.

Diving_Board
Gilead takes the plunge • Source: Shutterstock

Gilead Sciences Inc. is jumping into the increasingly busy pool of protein degradation R&D by tapping into Nurix Inc.’s technology platform in a deal that could be worth more than $2bn for the San Francisco-based firm.

Gilead’s aim is to create a pipeline that applies this type of scientific development specifically to cancer and other “challenging...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip